Site Logo
AAV Gene Therapy For Neuronopathic Gaucher Disease and Parkinson's Disease with a GBA Mutation webinar
2020-10-05 15:00:00

Taking place on Monday 5th Ocober from 3-4:30pm (BST), this is the second in a series of educational webinars for our members on the latest developments in gene therapy will focus on AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher disease and Parkinson's disease with a GBA mutation.

Dr Heather Lau from the NYU School of Medicine will moderate the call and our speakers will be Eriene Wasef (Medical Director) and Olga Uspenskaya-Cadoz (Vice President, Clinical Development) from Prevail.